There cur­rently are more than 300 clin­i­cal trials ongoing around the world that are investigating treat­ments for multiple myeloma and looking for patient par­tic­i­pants. Most of these trials are exploring new myeloma ther­a­pies that have not yet been approved for use outside of clin­i­cal trials, and many of these “investigational” ther­a­pies, as they often are called, have the poten­tial to be extremely effective.

The number of new treat­ments under devel­op­ment for multiple myeloma is greater than it ever has been, and this creates tremendous hope in the myeloma com­munity. In just a …

Newark, CA (Press Release) – Teneobio, Inc. a clin­i­cal-stage bio­technology com­pany devel­op­ing engi­neered bispecific anti­bodies for the treat­ment of cancer announced today that the first patient has been dosed with TNB-383B in a Phase 1 clin­i­cal study to eval­u­ate the safety and tolerability of its dif­fer­en­ti­ated anti-BCMAxCD3, a bispecific anti­body that redirects T-cells to kill multiple myeloma cells with minimal cytokine release. Earlier this year, Teneobio’s affiliate TeneoOne, Inc. and AbbVie entered a strategic part­ner­ship, giving AbbVie the exclusive right to acquire TeneoOne post-Phase 1 studies and lead the sub­se­quent global devel­op­ment and …

Genmab and BliNK Biomedical have entered into a commercial license agree­ment to develop novel bispecific thera­peutics based on BliNK Biomedical’s CD47 anti­bodies and Genmab’s DuoBody® Platform tech­nology.

Copenhagen, Denmark (Press Release) – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it has entered into an agree­ment with BliNK Biomedical for an exclusive commercial license to certain anti­bodies targeting CD47, for poten­tial devel­op­ment and com­mer­cial­iza­tion into novel bispecific thera­peutics created via Genmab’s pro­pri­e­tary DuoBody Platform tech­nology. This agree­ment sup­ports Genmab’s estab­lish­ed prod­uct pipe­line strategy. Under the terms of the agree­ment, Genmab will pay BliNK Biomedical an up­front fee of USD 2.25 million. BliNK Biomedical is also eli­gible to receive up to approx­i­mately USD 200 million in devel­op­ment, regu­la­tory and commercial mile­stone pay­ments for …

Newark, CA (Press Release) – Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that their inves­ti­ga­tional new drug appli­ca­tion (IND) for TNB-383B, a bispecific T-cell engaging anti­body for the treat­ment of multiple myeloma, was cleared for the initiation of Phase I clin­i­cal studies by the US Food and Drug Admin­istra­tion (FDA) on April 24th, 2019. The ongoing devel­op­ment of TNB-383B is being pursued in col­lab­o­ration with AbbVie, Inc.

TNB-383B is a fully human bispecific anti­body with two binding moieties for B-Cell Maturation Antigen (BCMA) on one arm and a unique anti-CD3 on …

North Chicago, IL and Menlo Park, CA (Press Release) – AbbVie (NYSE: ABBV), Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic trans­­action to develop and com­mer­cial­ize TNB-383B, a BCMA-targeting immuno­therapeutic for the poten­tial treat­ment of multiple myeloma.

B-cell maturation an­ti­gen (BCMA) has emerged as an attractive target for multiple myeloma thera­peutics. TNB-383B is a bispecific anti­body that simultaneously targets BCMA and CD3, utilizing Teneobio's unique anti-CD3 plat­form. Through this dual targeting mech­a­nism, TNB-383B is designed to direct the body's own immune system to target and …

Thousand Oaks, CA, and Ingelheim, Germany (Press Release) – Amgen (NASDAQ: AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global devel­op­ment and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation an­ti­gen (BCMA), a poten­tial target for multiple myeloma. BI 836908 (AMG 420) is cur­rently in Phase 1 studies. BI 836908 (AMG 420) was originally licensed to Boehringer Ingelheim by Micromet before the com­pany was acquired by Amgen in 2012.

Under the provisions of the agree­ment, Amgen will work with Boehringer Ingelheim to assume re­spon­si­bil­ity­ …